REMASTER

DEAD

Serial Number

90552860

Owner

Remix Therapeutics Inc.

Attorney

Christina M. Licursi

Filing Date

Mar 1, 2021

Add to watchlist:

No watchlists yet

+ Create New Watchlist

View on USPTO

REMASTER Trademark

Serial Number: 90552860

REMASTER is a trademark filed by Remix Therapeutics Inc. on March 1, 2021. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Trademark Classes

Class 5 - Pharmaceuticals

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Class 42 - Computer & Scientific

Scientific and technological services; industrial analysis and research services

Owner Contact Info

Remix Therapeutics Inc. (8 trademarks)

400 Technology Square
Cambridge, MA 02139

Entity Type: 03

Legal Representation

Attorney of Record

Christina M. Licursi

3,303 trademarks filed View all →

Correspondence Address

Christina M. Licursi WOLF, GREENFIELD & SACKS, P.C.

600 ATLANTIC AVENUE

BOSTON, MA 02210

United States

Trademark Details

Filing Date

March 1, 2021

Registration Date

Not Registered

Published for Opposition

November 9, 2021

Goods & Services

Pharmaceutical and therapeutic pharmaceutical preparations for the treatment of cancer, immune system related diseases and disorders, cardiovascular diseases and disorders, genetic diseases and disorders, rare and orphan diseases, and neurological diseases and disorders

Pharmaceutical, medical, scientific, and biopharmaceutical research and development; Scientific research, pharmaceutical research, medical research; Technical and scientific research consultation in the fields of biotechnology and development of pharmaceuticals; Product development for others in the fields of biotechnology and development of pharmaceuticals

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED

Oct 7, 2025 MAB6

ABANDONMENT - NO USE STATEMENT FILED

Oct 7, 2025 ABN6

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

Jul 2, 2024 EXRA

SOU EXTENSION 5 GRANTED

Jul 2, 2024 EX5G

SOU EXTENSION 5 FILED

Jul 2, 2024 EXT5

SOU TEAS EXTENSION RECEIVED

Jul 2, 2024 EEXT

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

Jan 6, 2024 EXRA

SOU EXTENSION 4 GRANTED

Jan 4, 2024 EX4G

SOU EXTENSION 4 FILED

Jan 4, 2024 EXT4

SOU TEAS EXTENSION RECEIVED

Jan 4, 2024 EEXT

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

Jun 30, 2023 EXRA

SOU EXTENSION 3 GRANTED

Jun 28, 2023 EX3G

SOU EXTENSION 3 FILED

Jun 28, 2023 EXT3

SOU TEAS EXTENSION RECEIVED

Jun 28, 2023 EEXT

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

Dec 30, 2022 EXRA

SOU EXTENSION 2 GRANTED

Dec 28, 2022 EX2G

SOU EXTENSION 2 FILED

Dec 28, 2022 EXT2

SOU TEAS EXTENSION RECEIVED

Dec 28, 2022 EEXT

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

Jan 12, 2022 EXRA

SOU EXTENSION 1 GRANTED

Jan 10, 2022 EX1G

SOU EXTENSION 1 FILED

Jan 10, 2022 EXT1

SOU TEAS EXTENSION RECEIVED

Jan 10, 2022 EEXT

NOA E-MAILED - SOU REQUIRED FROM APPLICANT

Jan 4, 2022 NOAM

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

Nov 9, 2021 NPUB

PUBLISHED FOR OPPOSITION

Nov 9, 2021 PUBO

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

Oct 20, 2021 NONP

APPROVED FOR PUB - PRINCIPAL REGISTER

Oct 1, 2021 CNSA

TEAS/EMAIL CORRESPONDENCE ENTERED

Sep 30, 2021 TEME

CORRESPONDENCE RECEIVED IN LAW OFFICE

Sep 30, 2021 CRFA

ASSIGNED TO LIE

Sep 29, 2021 ALIE

TEAS RESPONSE TO OFFICE ACTION RECEIVED

Sep 24, 2021 TROA

NOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED

Sep 23, 2021 GEAN

EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED

Sep 23, 2021 GEAP

COMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION AUTOMATIC ENTRY

Sep 23, 2021 EPEN

EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED

Sep 23, 2021 CPEA

ASSIGNED TO EXAMINER

Sep 22, 2021 DOCK

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

May 30, 2021 NWOS

Related Trademarks

More from this Owner

REMASTER

REMIX THERAPEUTICS

More in Same Class

ENDO THERAPEUTICS

Serial #90552932

EMD ELECTRONICS

Serial #90552430

HERBAME

DAVID SINCLAI